Isabella. M. Cattadori

Isabella. M. Cattadori

Auto-generated profile, based on publicly available information

Isabella. M. Cattadori

Center for Infectious Disease Dynamics and Department of Biology, The Pennsylvania State University, University Park

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Ecology
Verified
Journal Article
Closed access
PDF file
DHDrew Harvell
Drew Harvell
SASonia Altizer
Sonia Altizer
ICIsabella M. Cattadori
Isabella M. Cattadori
LHLaura Harrington
Laura Harrington
EWErnesto Weil
Ernesto Weil

1 August 2003 in International Journal for Parasitology
Verified
Journal Article
Closed access
SPSarah Perkins
Sarah Perkins
ICIsabella M. Cattadori
Isabella M. Cattadori
Valentina TagliapietraValentina Tagliapietra
Valentina Tagliapietra
Annapaola RizzoliAnnapaola Rizzoli
Annapaola Rizzoli
PHPeter Hudson
Peter Hudson

1 December 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
ESEric Salazar
Eric Salazar
Suresh V. KuchipudiSuresh V. Kuchipudi
Suresh V. Kuchipudi
PCPaul A. Christensen
Paul A. Christensen
TETodd Eagar
Todd Eagar
XYXin Yi
Xin Yi
JMJames M. Musser
James M. Musser
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the urgent need for assays that detect protective levels of neutralizing antibodies. We studied the relationship among anti-spike ectodomain (anti-ECD), anti–receptor-binding domain (anti-RBD) IgG titers, and SARS-CoV-2 virus neutralization (VN) titers generated by 2 in vitro assays using convalescent plasma samples from 68 patients with COVID-19. We report a strong positive correlation between both plasma anti-RBD and anti-ECD IgG titers and in vitro VN titers. The probability of a VN titer of ≥160, the FDA-recommended level for convalescent plasma used for COVID-19 treatment, was ≥80% when anti-RBD or anti-ECD titers were ≥1:1350. Of all donors, 37% lacked VN titers of ≥160. Dyspnea, hospitalization, and disease severity were significantly associated with higher VN titer. Frequent donation of convalescent plasma did not significantly decrease VN or IgG titers. Analysis of 2814 asymptomatic adults found 73 individuals with anti-ECD IgG titers of ≥1:50 and strong positive correlation with anti-RBD and VN titers. Fourteen of these individuals had VN titers of ≥1:160, and all of them had anti-RBD titers of ≥1:1350. We conclude that anti-RBD or anti-ECD IgG titers can serve as a surrogate for VN titers to identify suitable plasma donors. Plasma anti-RBD or anti-ECD titers of ≥1:1350 may provide critical information about protection against COVID-19 disease.

1 January 1999 in Trends in Ecology & Evolution
Verified
Journal Article
Closed access
PHPeter Hudson
Peter Hudson
ICIsabella M Cattadori
Isabella M Cattadori

1 February 2005 in Nature
Verified
Journal Article
Closed access
PDF file
ICIsabella M. Cattadori
Isabella M. Cattadori
DHDaniel T. Haydon
Daniel T. Haydon
PHPeter Hudson
Peter Hudson

1 December 2003 in Ecology Letters
Verified
Journal Article
Closed access
PDF file
NFNicola Ferrari
Nicola Ferrari
ICIsabella M. Cattadori
Isabella M. Cattadori
JNJavier Nespereira
Javier Nespereira
Annapaola RizzoliAnnapaola Rizzoli
Annapaola Rizzoli
PHPeter Hudson
Peter Hudson